Results 191 to 200 of about 681,456 (227)

Analytical comparison of Soliris® and its biosimilar, PRK-001

, 2020
Soliris® (Eculizumab) was approved by regulatory authorities as the first drag for treatment of orphan disease, paroxysmal nocturnal hemoglobinuria, in 2007.
M. A. Zhuchenko, N. Orlova, D. Zybin, V. V. Nikolaeva, A. Klishin, N. Lobanova, V. Soldatov, N. Romanova, Y. Seregin   +8 more
semanticscholar   +1 more source

Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022

BioDrugs, 2023
R. Kuribayashi, Ayuki Nakano, Aya Hariu, Y. Kishioka, Futaba Honda   +4 more
semanticscholar   +1 more source

HPR96 Trends in European Pharmaceutical Tender Requirements and Opportunities for Differentiation for Biosimilars

Value in Health, 2022
A Świder, P Borga, F Cousins
openaire   +1 more source

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

2014
223 ...
openaire   +1 more source

Biosimilars Pharmaceutical Market in India: Current Status, Challenges and Future Perspective

Bioscience Biotechnology Research Communications, 2021
openaire   +1 more source

HPR151 New Proposed European Commission Pharmaceutical Regulation – Potential Changes and Impact on Biosimilars

Value in Health, 2023
B. Yap, M. Watts
openaire   +1 more source

FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings – FORCE study

Eye
Ashish Sharma, Luke Nicholson, C. Vazquez-Alfageme, Vasuki Sivagnanavel, Riccardo Fausto, M. Soare, Marta Bautista Salamanca, Lorenzo Fabozzi, Chrysanthi Tsika, Olga Cejudo Corbalan, Alejandro Gomez Verdejo, Taku Wakabayashi, Se Joon Woo, Anton M. Kolomeyer, Hana A. Mansour, Bita Momenaei, C. Regillo, Baruch D. Anat Francesco Giuseppe Tomoko Masaaki Tomoko S Kuppermann Loewenstein Bandello Querques Ueda-Cons, B. Kuppermann, Anat Loewenstein, Francesco Bandello, Giuseppe Querques, Tomoko Ueda-Consolvo, Masaaki Ishida, Tomoko Nakamura, S. Yanagisawa, Atsushi Hayashi, Kotaro Tsuboi, Nilesh Kumar, N. Parachuri, Jay Sheth, Seemantini Ayachit, Chitaranjan Mishra, Debdulal Chakraborty, Alay Banker, K. Rezaei, A. Khanani, Peter K. Kaiser, F. Holz, S. Sivaprasad, Ş. Özdek, Kodjikian Laurent, Alper Bilgic, Paolo Lanzetta, Valentina Sarao, Caroline R. Baumal, Nancy Holekemp, Taiji Sakamoto, A. Tufail, Nicolas A. Yannuzzi, Jayanth Sridhar, Giulia Corradetti, A. Hilely, D. Boyer, Aleksandra Rachitskaya, T. Peto, Maximilian W. M. Wintergerst, Barbara Parolini, P. Mruthyunjaya, Quan Dong Nguyen, D. Do, P. Keane, Tarek Hassan, David A. Eichenbaum, Dilraj S. Grewal, Francesc March, Martin S. Spitzer, K. Falavarjani, Martin S. Zinkernagel, C. Lee, Judy E. Kim   +70 more
semanticscholar   +1 more source

Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia

European Journal of Haematology, 2023
Elena Inzoli, Elena Crisa, Novella Pugliese   +2 more
exaly  

Impact of a clinical pharmacist in a multidisciplinary consultation on the switch to a biosimilar for inflammatory rheumatic diseases

Joint Bone Spine, 2022
Clementina López-Medina, Christian Roux, Ornella Conort   +2 more
exaly  

The pharmaceutical industry tussles over biosimilars: federal and state decisions will have a big impact on pharmacists.

P & T : a peer-reviewed journal for formulary management, 2014
Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
openaire   +1 more source